A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study wants to see how well a medicine called JNJ-68284528 can help people get rid of a disease in their body. They will look at how many people were able to completely get rid of the disease.
This study wants to see how well a medicine called JNJ-68284528 can help people get rid of a disease in their body. They will look at how many people were able to completely get rid of the disease.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.